Member Info for Wigster77

Thanks Jint

BARDA are doing an on-line event about host-based therapeutics. Not directly involving Synairgen or anything, but should be an interesting watch to see their latest thoughts and strategies. You never know - we might get a mention...

-------------

Join BARDA program managers and the New Orleans BioInnovation Center for a discussion on the current and future direction of host-based therapeutics

Host-directed therapeutics have the potential to prevent and treat disease, agnostic to which virus or bacteria causes the infection. Innovative products in this space can be a powerful tool during a health security crisis.

Please join BARDA program managers on August 22 1:30-3 p.m. ET as they join the New Orleans BioInnovation Center to discuss current and future directions of host-based therapeutics. Attendance is free.

eventbrite.com/e/barda-host-directed-therapeutics-hdtx-information-session-tickets-395490862817

"Can anyone on here remind me what was said at the Q&A session re winter trials ? I’ve asked Brookes but no reply and cant locate anything on the website . Thank you . "

Courtesy of Graham201986 who was also at the AGM:
Maybe the biggest one of them all missing from the Q&A (notes from me and Doc 83) happy to add on. Q; do you see Syn treating patients in a hospital either in the UK or US this winter? ARM I would envisage yes, I'm happy to say we strongly envisage we will be. Subject to ongoing discussions.

That's a fair question Tatty.

I do remember comprehensive questions and responses around SOC (and indeed other things like the choice of Endpoints) at the AGM, but can't remember one in the specific context you highlight. I may have missed it though as, like I say, some of the answers given were very lengthy and thus made it impossible to jot every point down. Maybe one of the other attendees can add more....

One thing I would say is that if they did know (or at least suspect) that SOC inclusion would severely compromise SNG001's trial results early-ish in the trial then why did they continue "full steam ahead" with new hires, collaborations and preparations for commercialisation right up until Doomsday?

GLA!

He certainly wasn't one of the ones on the top table and I don't recall seeing him anywhere else in the room, although it is possible I missed him.

He's more than welcome to demonstrate to us how exceptional he is for Synairgen as far as I'm concerned.

Just believe the RNSs. Most of the other stuff is attention-seeking rubbish.

Keep up with the cautious optimism Mani, hopefully soon your positivity will be rewarded!!

Either way, I hope we...and others...will be able to meet at Big Johnny's and chew the fat over this most interesting of investments sometime soon :-)

All the very best to all!!!!

Great research all, let's hope it's good news for us. It'd be nice for us to be able discuss positive stuff rather than the infighting which has sadly plagued the board recently.

Just need to check in on Manifesto, who is remarkably restrained on this *potential* good news...please check you've not ordered alcohol-free wine by mistake ;-)

All the very best to all :-)

Does the role of Senior Medical Writer involve writing RNSs? If so, I hope we see the a bit more positive language used and an end to good news being buried so deep that you struggle to find it!!

It would certainly seem bizarre for them to completely wash their hands of Synairgen/SNG001 after putting it through a (what I would imagine to be) expensive P2 trial, the initial results of which showed enough promise for the drug to pass through to Phase 3...

Thanks Tommy - will be interesting to see what he says

Many thanks Tommy for your continued in-depth analysis of information you or others have found and put onto this board.

I note that Dr Adam mentions (and also referenced on slide 29) a 2-day "public forum discussion" conducted with the help of the FDA and all stakeholders, to discuss the best ways forward - I would like to think that Synairgen were heavily involved in this. Certainly based on RM's "we're in regular contact with the ACTIV2 team - I spoke to them yesterday as it happens" comment at the AGM would suggest that they're kept well in the loop.

She mentions that the slides and write-ups from these discussions could be made public if people are interested - if anyone's got her contact details it might be worth requesting these.

If it is believed that SNG001 would be highly beneficial to helping with Long Covid (based on the INF research kindly supplied by Tommy - many thanks), then what would be the process of getting towards an EUA/approval - would this be yet another trial, similar to the SPRINTER/ACTIV ones but with more Long Covid-focussed endpoints? If so, I wonder what these endpoints would be?

RM said that Synairgen don't have the resources to investigate every sub-variant of Covid, but this BA 2.75 seems to be a particularly tricky customer...if they could prove that SNG001 works well against it - even just via In-Vitro data - then that could be a very useful boost to their arguments to be included on further trials.

"Take a look at the list of people they employ on LinkedIn and most of them have impressive CVs and I imagine salaries to match however what the hell are they all doing on a 9-5 basis. What work actually needs doing or is being done?"

Impressive CVs indeed Mr Costs, which does kind of inspire a bit of confidence that they've got the right calibre of people - if they're being utilised effectively of course. Salaries - looking at some of the salaries we do know (mentioned in the annual report), I would guess that you're looking at £100-200K+ for the rest of the "senior" team.

As to what they're doing now - a similar question was asked at the AGM (specifically about all of the new hires prior to Sprinter results) and the basic answer was that everyone who was taken on to assist with commercialisation of SNG001 in anticipation of good Sprinter results were currently assisting in the "at haste" work to get on a new trial for SNG001 as this was obviously the burning priority at the moment - and these employees have the necessary skills and contacts to be of great use on this task.

I'm trying to be patient, but the clock is ticking and it's easy to slip into frustration with each passing day without new news (as this board has shown over the last day or so!!). I think asking what Synairgen are doing in more detail on a day-to-day basis is a fair question to ask given the high salaries being paid, but doubt very much whether we'd ever get an answer to that.

Ultimately, even if we did get an answer, it may well be impossible for it be anything other than vague because a lot of the next steps are out of Synairgen's hands...and that's the bit that concerns me the most.

DYOR & GLA!

Thank you all. The great levels of appreciation shown on here to Doc, I and other AGM attendees far outweigh the odd barbed comment. I've long said that the best thing about this particular board is its wide balance of comments, be-it on the very positive side (hello Manifesto!!), through to the more cautious and negative sides. All can be useful when said in a constructive manner. And of course the useful information that the many super-sleuths provide is appreciated too.

Tattyhead61 - Your personal attacks on me this morning were very surprising and not nice for me to read.

If the fact a person attends the AGM of a company they're invested in makes them a "star struck clown" then there must be a lot of "star struck clowns" in the world.

What is your justification to say that I and others were "completely bamboozled" and "railroaded"? Do you know us? Do you know how we think and act?

How do you know that the AGM was a sham when you didn't attend?

How do you know that RM and the board "contribute nothing of value to the company"?

For many months you have come across as very bitter as you've lost a lot of money and have chosen to relentlessly lobby for the removal of RM and the board to the point of obsession. Now you resort to personal attacks as well.

I have a paper-loss probably similar to yours. I understand your bad-feeling and pain for where the SP is right now.

Me? I'd rather take a bit of personal responsibility for my predicament and do something constructive about it rather than moan on a bulletin board. Something like meeting the people from the company where (some of) my money is invested - at an AGM for example. So I can talk to them, question them, assess them and draw my own measured conclusions for what the future may or may not hold.

If that makes me a "star struck clown" then so be it.

Thanks nessab and fair play to Detective Aim...s/he gives Columbo a run for his money.

Hi Palladin - I came out of the meeting feeling extremely positive.

I was, like most people, extremely disappointed by the Sprinter results, but after the initial shock decided to take a more pragmatic view rather than demanding heads on pikes like some people did. However, I didnt travel over 100 miles to get fobbed off by flannel. We put forward some very direct, probing and difficult questions (many of which were thanks to members on here) and none were dodged and all answers seemed genuine. Not all members of the board were amazingly eloquent, but this was largely the ones with "backroom" roles rather than customer-facing roles.

Commercialisation was talked about, both in terms of likelihood and timelines and it was clear that this is their primary objective - however it will take time. Someone asked directly whether this would take place within the next 12 months and Simon Shaw (if memory serves) stated "highly unlikely". Realistic rather than the answer we wanted to hear.

I guess my positivity was mostly cemented by the chats with Sir Stephen Holgate, Richard Marsden and Dr. Bruce Campbell after the meeting. The main point I took away is that these guys are extremely passionate about the product and its usefulness and need on the world stage. They say they are working "at haste" - hopefully they are...we have no way of knowing for certain - but one thing was clear: they're not going to rush this for a quick buck. They know they need to build a formidable, robust case for SNG001 to maximimise it's commercial value. They were all very calm and the belief in the product shone through. Dr. Bruce Campbell particularly cited an example of a similar process he'd been involved with previously at another pharma where trial results and market caps were up and down like a yoyo and there was a calm "I've been doing this for years...SNG001 will come good" air in his comments.

So, that's my take, my personal view, based on my assessment of what I saw. I'd love to hear the views of other attendees - you may well get a totally different viewpoint. As I said, I'm probably more on the pragmatic end of the scale, but I was closely watching HOW they answered the questions as well as the content of the answers and it all seemed genuine to me, hence me leaving feeling very positive.

DYOR & GLA!